
Medicine and Health
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
P. Eijsvogel, P. Misra, et al.
This groundbreaking 44-week study explores UB-312, an innovative immunotherapeutic approach targeting pathological αSyn in Parkinson's disease patients. With safety and immunogenicity confirmed, findings indicate a significant reduction in αSyn seeds, paving the way for further development. Conducted by a team of experts, these promising results are a step forward in Parkinson's research.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.